

Guideline Development Group Declaration of Interests

Medicines Concordance

John

University Lecturer in General Practice

1. Personal specific pecuniary or personal family interest:

19/09/07
Grant for research into Patient preference about risk communication - £181,268 awarded 2006.

28/02/07
Non Specific pecuniary interest
Shares in GSK, tesco, Unilever

5th GDG meeting
Research into Patient preferences about risk communication - £181,268 awarded 2006.

2. Personal family interest:

3. Non-personal pecuniary interest

11/07/07
Appointed Non Executive Director, Weast Suffolk Hospital Acute Trust

4. Personal non-pecuniary interest:

Jim

Senior Lecturer Learning Disabilities

1. Personal specific pecuniary or personal family interest:

Nothing to declare

11/07/07
Invited to be a trustee by signalong

2. Personal family interest:

3. Non-personal pecuniary interest Nothing to declare

4. Personal non-pecuniary interest:

Blair

Alison

Chief Executive Officer Acne Support Group

1. Personal specific pecuniary or personal family interest:

Bowser

Medicines Concordance

2. Personal family interest:

3. Non-personal pecuniary interest Donations to the acne support group, which I am chief executive to. There are unconditional general fund donations and I do not receive any direct payment from any company. (Valeant Pharma; Galderma UK; Steifel Labs)

4. Personal non-pecuniary interest:

Wendy

Clyne

Assistant Director, Medicines Partnership Programm

1. Personal specific pecuniary or personal family interest:

09/04/08

1. Author's fee for article in 'The Pharmacist' about concordance.
2. Author's fee for article in 'Prescriber' about concordance.
3. Fee for workshop on concordance for pre-registration pharmacists for the NPA.
4. In negotiation phase with European Commission 7th Framework Programme as a co-applicant for a EUR 2.1 million research grant on patient compliance.

09/05/07

Paid speeches

11/07/07

Involved in a GSK ran concordance programme

2. Personal family interest:

3. Non-personal pecuniary interest

22-01-09

NPC Plus has been commissioned to deliver adherence workshops from several PCTs – Lincolnshire, Solihull and Nottingham County.

NPC Plus has been commissioned by Stoke-on-Trent PCT to develop a community pharmacy long term condition adherence support service

Participation in advisory board for patient compliance support programme - LUNDBECK

General Non - Current interests

Next 12 months, commission to train practitioners in concordance consultation skills

With GSK, Sanofi-Aventis, Shering Plough

4. Personal non-pecuniary interest:

Peter

Crome

Professor of Geriatric medicine

1. Personal specific pecuniary or personal family interest:

09/04/08

1. I am attending the Brazilian Congress of Gerontology in June. My travel and hotel costs are being provided by Novartis Brazil with whom I have no connection.
2. I am hoping to undertake a clinical trial of a putative anti-dementia drug manufactured by Lilly. This contract is not yet signed.

Medicines Concordance

28/02/07

Joint share ownership with Prof. L Crome - GSK

Chaired symposium in Oct 2006
subject - Pain control in older people
Organisation - NAPP

11/07/07

Have a personal pecuniary interest in that I have shares in GSK but as far as I know no GSK product was discussed

I also have a non pecuniary interest in that I have published on concordance, compliance etc.

2. Personal family interest:

3. Non-personal pecuniary interest 28/02/07

Research group - Dementia Drug trials - Ongoing
Organisation - Stive, Eisai,

4. Personal non-pecuniary interest:

28/02/07

I also have a non pecuniary interest in that I have published on concordance, compliance.

Peter

Haddad

Consultant Psychiatrist and Honorary Senior Lecturer in
Psychiatry

1. Personal specific pecuniary or personal family interest:

21/11/08

Lecture fees paid by Janssen
Consultancy fee from Janssen

10/10/08

1) Lecture fees (Astra-Zeneca, Janssen, Lilly, Valeant).

2) Fees for consultancy (e.g. advisory boards) Eli Lilly (Advisory board on antipsychotic) Janssen (Advisory board on non-clinical education).

28/02/07

1. Lecturer fees - Astra Zeneca, Eli Lilly, Janssen-Cilag

2. Fees for consultancy: Eli Lilly, Janssen- Cilag

n.b the above list summarises my involvement with the pharmaceutical industry in the last 12 months. Please note that, with one exception, I doubt that the above fees have any relevance to this guideline as the lecturing and consultancy were not related to compliance but rather dealt with specific psychiatric illnesses (depression, schizophrenia, bipolar disorder) or treatments (antidepressants, antipsychotics). The one exception is that my work with Janssen-Cilag has related to the use of long acting injections of antipsychotic which can improve compliance in some patients with schizophrenia and other psychoses

2. Personal family interest:

10/10/08

None

Medicines Concordance

3. Non-personal pecuniary interest 10/10/08
None

28/02/07

Co-Investigator in an on-going investigator-led study of quetiapine as an augmenting agent in treatment-resistant depression. The grant for this study came from Astra-Zeneca and is held by the principal investigator, not myself, at Manchester University. I received no payment for contributing to this study. I do not believe that this grant has any relevance to this guideline (the study has nothing to do with adherence) but I have mentioned it for the sake of completeness.

02/07/08

A hospital administrator contacted me to inform me that on reviewing the research contract some money from the above study was actually payable to my research fund at the Trust and this payment has subsequently been made into my Trust research fund. I have not taken any private payment. The sum of money paid into my Trust research fund was less than £3000.

Payment from my research fund for work as a Co-Investigator in an on-going investigator-led study of quetiapine as an augmenting agent in treatment-resistant depression. The grant for this study came from Astra-Zeneca.

4. Personal non-pecuniary interest:

10/10/08

1. I am a co-investigator in an industry sponsored (Lilly) observational study that investigates predictors and consequences of antipsychotic non-adherence in schizophrenia. (Lilly).

2. I am a co-author of a review of conventional antipsychotic depots that will appear in a peer-reviewed supplement sponsored by industry (Lilly).

01/07

I hold the view and have expressed it in writing, that long acting antipsychotic injections may improve adherence, compared to oral antipsychotics, in some patients with schizophrenia. This view is consistent with the evidence, existing NICE guidance (e.g. 2002 schizophrenia guidance) and the views of many psychiatrists.

This view could be regarded as favouring companies that manufacture long acting antipsychotic injections e.g Janssen-Cilag.

02/07/08

Since joining the GDG in Feb '07 I have attended several medical conferences (all on a range of psychiatric subjects and organized by independent bodies) with my associated expenses being paid by various drug companies.

26/02/08

1. Lecture Fees (Bristol-Myers-Squibb: Lecture on antipsychotic side-effects)

2. Fees for consultancy (i.e. advisory boards) Eli Lilly (re: antipsychotics), Servier (re: antidepressants).

NB: The above list summarises my involvement with the pharmaceutical industry since the last NICE Meeting in Jan '08/16/01/08

1. Lecture Fees (Eli Lilly Janssen-Cilag)

2. Fees for Consultancy (Astra-Zeneca, Eli Lilly, Janssen-Cilag, Bristol Myers Squibb)

NB: The above list summarises my involvement with the pharmaceutical industry since my last declaration of interest. My work with Janssen-Cilag relates to the use of long acting

Medicines Concordance

injections of antipsychotics which can improve compliance in some patients with schizophrenia and other psychoses. Other than this the above fees do not appear to have any relevance to this guideline as the lecturing and consultancy were not related to adherence but rather dealt with specific psychiatric illnesses (schizophrenia, bipolar disorder) or treatments (antidepressants, antipsychotics).

19/09/07

1. Lecture fees (Eli Lilly ,Janssen-Cilag)

NB: The above list summarises my involvement with the pharmaceutical industry since the third NICE Meeting in July. My Work with Janssen-Cilag relates to the use of long acting injections of antipsychotics which can improve compliance in some patients with schizophrenia and other psychoses. The lectures for Eli Lilly do not appear to have any relevance to this guideline as they were not related to adherence but rather dealt with other areas including research methodology and observational studies.

Steven

Hemingway

Senior Lecturer in Mental Health

1. Personal specific pecuniary or personal family interest:

07/03/07

1. Honorarium for speaking at an educational event. South London April 2007
2. Honorarium for speaking at an educational event. Leeds December 2007. Both for Pharmaceutical Janssen-Cilag LTD

02/07/08

Funding to attend ECE conference in Berlin by EISAI.

2. Personal family interest:

3. Non-personal pecuniary interest

11/07/07

£500 Educational Grant from Janssen-Cilag Ltd to partially support me attending the Australian College of Mental Health Nurses Conference in Cairns Australia October 2007.

4. Personal non-pecuniary interest:

Robert

Horne

Professor of Behavioural medicine

1. Personal specific pecuniary or personal family interest:

22/01/09

Paid consultancy and lectures to Proctor and Gamble, Shire Pharmaceuticals and Astellas.

02/07/08

June 08 Grand Round at Merck Outcomes USA-paid
Talk on adherence in HIV for BMS on 4th July 2008- paid
Consultancy on adherence research to shire pharmaceuticals
Consultancy on adherence to GSK
Consultancy on adherence in IBD to Procter and Gamble

28/02/07

1. Paid consultancy work advising on research and audit programmes to monitor patient perspectives of illness and treatment and adherence to medication.
2. Speaking engagements at national and international conferences and advisory boards

Medicines Concordance

presenting academic data adherence to medication across chronic illness

Activities 1. and 2. for the following companies; GlaxoSmithKline, Pfizer, Boeringher Ingelhiem, AstraZeneca, Abbott, Gilead, Novartis, ALTANA Pharma, Shire, Roche, Servier, Aventis, MSD, Proctor and Gamble, Schering Plough. Hamell

3. The above consultancy work is promulgated through a limited company with my wife Carol Elizabeth Kirkman-Horne

4. In addition, I am director of a new company Optimum Patient Care Ltd developing research-base programmes to facilitate the assessment of patient perspectives of illness and treatment in the review of chronic illness in primary care.

2. Personal family interest:

3. Non-personal pecuniary interest 22/01/09

Received unrestricted educational grants to the School of Pharmacy, University of London from Proctor and Gamble, Shire Pharmaceuticals, National Institute of Health Research (NIHR) for research into patient benefit and adherence to medication.

02/07/08

Awarded unrestricted educational grant to University of London to conduct research into patient perspectives and adherence to phosphate reduction treatments in renal disease for Shire pharmaceuticals £100k 2008-2009.

28/02/07

I have received unrestricted educational and research grants to my university-based research programme from a range of pharmaceutical companies.

- GlaxoSmithKline, Pfizer, Boeringher Ingelhiem, AstraZeneca, Abbott Gilead, Novartis, Shire, Roche, MSD

30/01/07 have received unrestricted educational and research grants to my university-based research programme from a range of pharmaceutical companies: GlaxoSmithKline, Pfizer, Boeringher Ingelhiem, AstraZeneca, Abbott, Gilead, Novartis, Shire, Roche, MSD,

4. Personal non-pecuniary interest:

09/05/08

Approached by Buzienker to give a speech on MC in May, but did not attend.

Approached by Chandler Chicco to request advice on support service for patients with HIV.

30/01/07

I have developed several questionnaire-based tools for assessing patients perspectives of illness and treatment and adherence to medication

Shaun

Patient Representative

1. Personal specific pecuniary or personal family interest:

Member of Board of Directors LAMP (the leicestershire action for mental health project)

Member of Policies Committee (Mind)

Member of publications committee

Member of Mind link national advisory panel

Johnson

Medicines Concordance

2. Personal family interest:

3. Non-personal pecuniary interest

4. Personal non-pecuniary interest:

Sean

Kelly

Consultant Physician and Gastroenterologist

1. Personal specific pecuniary or personal family interest:

2. Personal family interest:

3. Non-personal pecuniary interest

4. Personal non-pecuniary interest:

Member of British Society of Gastroenterology
Fellow of the Royal College of Physicians
Lecturer Hull York Medical School.

Bunis

Packham

Nurse Consultant- Thrombosis and Anticoagulation

1. Personal specific pecuniary or personal family interest:

Nurse consultant- interested in standards and quality.
Keen to be involved in development of national guidelines.

2. Personal family interest:

3. Non-personal pecuniary interest

09/05/07
Invited by a scientific group to discuss MC. Non-paid role.

21/05/08
Asked to do a presentation on medication review for anticoagulation patients for NPC which is a follow on from the Medication review Level 2 in 2002

4. Personal non-pecuniary interest:

Member of Royal College of Nursing
Chair of Anticoagulation Specialist Association
Core Member of The Patient Safety Campaign 2008- VTE Lead

Mahendra

Patel

Lecturer/Research Fellow

Medicines Concordance

1. Personal specific pecuniary or personal family interest:

19/09/07

Guest speaker for the Cardio-diabetes event in collaboration with multiple organisations, held at the Barbican Theatre (London) to address Health inequalities: 'Mending the Gap: reducing cardiovascular risk in London (October 2007)'. I was paid an honorarium as a guest speaker for this event (plus travel expenses). The Honorarium offered was £200.00. I am attaching a copy of the event details for your information. As mentioned I have also just recently been appointed an Honorary Research Fellow at the University of Huddersfield.

28/02/07

Occasional professional services provided as a locum community pharmacist for Sainsbury's Pharmacy, Gordans Chemist Ltd, National CO-OP Ltd and other community pharmacy outlets

21/05/2008

Presentation at the conference Cardiopneumo in Italy 15-17 May 2008. Third International Conference on Cardiovascular and Respiratory Disease in Family Medicine. Implementing cares closer to home: the PhwSI's role

2. Personal family interest:

3. Non-personal pecuniary interest

28/02/07

1. Part of a Phd Research programme by Merck Sharpe & Dohme (2005): analysing medicines management for patients discharged from hospital following a current CHD event and comparing differences and effects of pharmacist intervention within white and South Asian groups.

Joint supervising of PhD student in within this area.

For School of Pharmacy - University of Bradford

2. Developing and delivering a training programme to health advocates, health carer and interpreters working as volunteers primary within communities of BME groups - British Heart Foundation.

For Institute of Pharmaceutical Innovation (IPI) - University of Bradford.

4. Personal non-pecuniary interest:

Member of the royal Pharmaceutical Society (GB)

member of the Cardiovascular Group - South Asian Health Foundation

Member of the Ethnic Health Strategy Group - British Heart Foundation

Trustee Member - Mouth Cancer Foundation

Research fellow - University of Bradford

Henry

Smithson

General Practitioner

1. Personal specific pecuniary or personal family interest:

21/11/08

Attended ECE in Berlin- no conflict of interests

21/05/08

Medicines Concordance

Funding to attend ECE congress in Berlin by EISAI

09/04/08

Advisory Board for Carisbamate Health Ec Meeting (Janssen-Cilag)

28/07/07

Various honoraria from USB, Pfizer and Eisai for educational initiatives relating to care of epilepsy

14/11/2007

Speaker honorarium and chairs honorarium for a Vagal Nerve Stimulation meeting in Manchester funded by the manufacturers last month. Total came within allowed amounts

2. Personal family interest:

3. Non-personal pecuniary interest

4. Personal non-pecuniary interest:

Jonathan

Steel

GP, Chairman GP Corniitte RCP

1. Personal specific pecuniary or personal family interest:

1. General Practitioner -Gloucester PCT
2. Fellow -Royal College of Physicians
3. Clinical Associate - Price Waterhouse Coopers

Has been invited by ABPI to their president's Gala Dinner in April- has offered to decline in case of incompatibility with NICE.

2. Personal family interest:

3. Non-personal pecuniary interest

11-07-07

Met with Sanofi-Aventis who paid for dinner, more in relation to the work I am doing at RCP, I have not accepted any work.

4. Personal non-pecuniary interest:

Sarah

Willett

1. Personal specific pecuniary or personal family interest: None

2. Personal family interest: None

3. Non-personal pecuniary interest None

Medicines Concordance

4. Personal non-pecuniary interest: None

Marian

Cotterell

Information Scientist

1. Personal specific pecuniary or personal family interest: None

2. Personal family interest: None

3. Non-personal pecuniary interest None

4. Personal non-pecuniary interest: None

Julie

Neilson

Health Services Research Fellow

1. Personal specific pecuniary or personal family interest: None

2. Personal family interest: None

3. Non-personal pecuniary interest None

4. Personal non-pecuniary interest: None

Vanessa

Nunes

Health Services Research Fellow/Project Manager

1. Personal specific pecuniary or personal family interest: None

2. Personal family interest: None

Medicines Concordance

3. Non-personal pecuniary interest

None

4. Personal non-pecuniary interest:

None

Norma

O'Flynn

Clinical Director

1. Personal specific pecuniary or personal family interest:

DOI - 06/03/07
Work half time as NHS general practitioner

2. Personal family interest:

None

3. Non-personal pecuniary interest

None

4. Personal non-pecuniary interest:

None
